(Q38373221)

English

A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 September 2017

A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer (English)

1 reference

Europe PubMed Central

2 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

peritoneal carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Rebecca Kristeleit

1

1 reference

Europe PubMed Central

2 September 2017

Irina Davidenko

2

1 reference

Europe PubMed Central

2 September 2017

Vadim Shirinkin

3

1 reference

Europe PubMed Central

2 September 2017

Fatima El-Khouly

4

1 reference

Europe PubMed Central

2 September 2017

Igor Bondarenko

5

1 reference

Europe PubMed Central

2 September 2017

Michael J Goodheart

6

1 reference

Europe PubMed Central

2 September 2017

Vera Gorbunova

7

1 reference

Europe PubMed Central

2 September 2017

Carol A Penning

8

1 reference

Europe PubMed Central

2 September 2017

Jack G Shi

9

1 reference

Europe PubMed Central

2 September 2017

Xiangdong Liu

10

1 reference

Europe PubMed Central

2 September 2017

Robert C Newton

11

1 reference

Europe PubMed Central

2 September 2017

Yufan Zhao

12

1 reference

Europe PubMed Central

2 September 2017

Janet Maleski

13

1 reference

Europe PubMed Central

2 September 2017

Lance Leopold

14

1 reference

Europe PubMed Central

2 September 2017

Russell J Schilder

15

1 reference

Europe PubMed Central

2 September 2017

language of work or name

0 references

publication date

8 July 2017

1 reference

Europe PubMed Central

2 September 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

2 September 2017

146

1 reference

Europe PubMed Central

2 September 2017

3

1 reference

Europe PubMed Central

2 September 2017

484-490

1 reference

Europe PubMed Central

2 September 2017

Cancer statistics, 2016

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.07.005

7 January 2021

Recent progress in the diagnosis and treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.07.005

7 January 2021

Treatment options in recurrent ovarian cancer: latest evidence and clinical potential

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.07.005

7 January 2021

Optimal treatment for relapsing ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.07.005

7 January 2021

Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.07.005

7 January 2021

Ovarian cancer creates a suppressive microenvironment to escape immune elimination

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.07.005

7 January 2021

Cellular immunotherapy for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.07.005

7 January 2021

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.07.005

7 January 2021

Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type and BRCA1 loss

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.07.005

7 January 2021

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.07.005

7 January 2021

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.07.005

7 January 2021

Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.07.005

7 January 2021

Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.07.005

7 January 2021

Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.07.005

7 January 2021

Tryptophan catabolism and regulation of adaptive immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.07.005

7 January 2021

Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.07.005

7 January 2021

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.07.005

7 January 2021

First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.07.005

7 January 2021

Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.07.005

7 January 2021

C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.07.005

7 January 2021

Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evalu

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.07.005

7 January 2021

Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.07.005

7 January 2021

Indoleamine 2,3 dioxygenase and metabolic control of immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.07.005

7 January 2021

Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.07.005

7 January 2021

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.07.005

7 January 2021

PD-L1 biology in response to chemotherapy in vitro and in vivo in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.07.005

7 January 2021

Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.07.005

7 January 2021

Identifiers

10.1016/J.YGYNO.2017.07.005

1 reference

Europe PubMed Central

2 September 2017

1 reference

Europe PubMed Central

2 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38373221&oldid=1962243467"